Collegium Pharmaceutical, Inc. has recently released its 10-K report, detailing its financial performance and operations for the year ended December 31, 2025. The company, headquartered in Stoughton, Massachusetts, is a specialty pharmaceutical firm focused on the development and commercialization of medicines for pain management. Its portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR, and Symproic, catering to the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain.
The 10-K report provides a comprehensive overview of Collegium Pharmaceutical's financial condition and results of operations. The company's product revenues, in accordance with Accounting Standards Codification Topic 606, were generated from sales of Jornay PM, Belbuca, Xtampza ER, the Nucynta Products, and Symproic. The report also details the cost of product revenues, including amortization and impairment expenses for intangible assets acquired, royalty expenses, and the cost of producing finished goods.
Collegium Pharmaceutical's research and development expenses historically consisted of product development, clinical and non-clinical activities, and costs associated with conducting clinical and non-clinical trials. However, as of April 1, 2022, the company redirected resources from research and development activities, focusing entirely on commercial products.
Moreover, the report outlines the selling, general, and administrative expenses, which primarily consist of salaries, employee-related costs, sales, marketing, market access, facility-related costs, and professional fees. The company expects these expenses to continue to be substantial for the foreseeable future as it invests in the commercialization of its products.
In terms of financial operations, Collegium Pharmaceutical's 10-K report also delves into interest expense, interest income, and the provision for income taxes. The report emphasizes the critical accounting policies and estimates, including revenue recognition, product revenue, sales deductions, and provisions for rebates and incentives, as well as product returns.
Today the company's shares have moved -2.77% to a price of $45.60. For more information, read the company's full 10-K submission here.
